AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles and preparation method and use thereof

The preparation of AO double-valent foot-and-mouth disease virus epitope chimeric nanoparticles through a prokaryotic expression system has solved the problem of insufficient immunogenicity of the existing vaccines and achieved stronger immune stimulation effects and broad-spectrum protection.

CN115057941BActive Publication Date: 2024-11-15LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202210501097.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-05-09
Publication Date
2024-11-15
Estimated Expiration
2042-05-09

AI Technical Summary

Technical Problem

The existing foot-and-mouth disease virus epitope vaccines have defects such as small molecular weight, weak immunogenicity, and easy decomposition, making it difficult to cause a strong and lasting immune response.

Method used

AO bivalent foot-and-mouth virus epitope chimeric nanoparticles were prepared by self-assembly of the skeleton protein by self-assembly of the skeleton protein, increasing the molecular weight of the antigen epitope and fully displaying it on the particle surface, and connecting multiple peptides with immune enhancement effects in series to enhance antigen extraction and immunostimulation effects.

Benefits of technology

It improves the immunogenicity of nanoparticles, can stimulate animal bodies to produce specific antibodies, significantly improves the level of neutralizing antibodies against type A and type O foot-and-mouth disease viruses, and provides a more effective and broad-spectrum vaccine strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003634334120000011
    Figure HDA0003634334120000011
  • Figure HDA0003634334120000012
    Figure HDA0003634334120000012
  • Figure HDA0003634334120000021
    Figure HDA0003634334120000021
Patent Text Reader

Abstract

The present invention discloses a preparation method and application of AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles. The AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles of the present invention are composed of epitopes of type A and type O foot-and-mouth disease virus in series with two skeleton proteins. The present invention selects T cell epitopes and B cell epitopes of structural proteins and non-structural proteins of type A and type O foot-and-mouth disease virus, connects them in series to skeleton protein A, and then selects multiple peptide segments with immune enhancement effects to connect them in series to skeleton protein B, and then inserts the gene sequences of the two optimized proteins into a prokaryotic vector, and obtains the AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles after prokaryotic system expression, purification, and self-assembly. The AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles of the present invention can be used to prepare vaccines for preventing diseases caused by type A and type O foot-and-mouth disease virus. In addition, the nanoparticle skeleton in the present invention can also be used to connect epitopes of other viruses in series to prepare related vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an epitope nanoparticle and a preparation method and use thereof, in particular to an AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticle and a preparation method and use thereof, belonging to the field of agricultural science, animal husbandry and veterinary science and technology. Background Art

[0002] Foot-and-mouth disease (FMD) is an acute, febrile and highly contagious natural epidemic disease caused by foot-and-mouth disease virus (FMDV). Foot-and-mouth disease is one of the animal infectious diseases that the World Organisation for Animal Health (OIE) is required to report to it. FMDV is a single-stranded positive-strand small RNA virus belonging to the Picornaviridae family and the genus Aphthovirus. Its hosts include pigs, cattle, sheep and other even-toed ungulates. This virus is a non-enveloped icosahedral particle composed of a viral genome and a viral capsid, with a diameter of between 25 and 30 nm. There are seven serotypes of FMDV, including type A, type O, type C, Asian type 1, South African type 1, South African type 2 and South African type 3. FMDV is prone to mutation, and each serotype includes multiple subtypes. There is no cross-protection between serotypes and subtypes, and a vaccine matching the prevalent wild-type strain is required.

[0003] With the development of biotechnology in recent years, bioinformatics prediction has overcome the shortcomings of traditional methods, such as long time consumption and high cost, and can identify antigen epitopes more conveniently and quickly. Antigenic epitopes refer to special chemical groups in antigen molecules that determine antigen specificity. They are the basic structural units for antigens to bind specifically to T and B cell antigen receptors (TCR / BCR) or antibodies, and are usually composed of 5 to 15 amino acid residues or 5 polysaccharide residues or nucleotides. At present, the main strains prevalent in my country are O and A types, including multiple subtypes (such as Mya98 genotype, Pan-Asian genotype, Ind2001 genotype, and A / GDMM / CHA / 2013 genotype, etc.). Studies have shown that the nucleic acid sequences of type A and type O FMDV are about 86% identical, and the antigens of type A FMDV are roughly similar to those of type O. The determination of these antigens provides an important basis for the screening of antigenic epitopes.

[0004] Since the RNA polymerase of FMDV lacks a proofreading mechanism, its genomic RNA exhibits a very high mutation rate, while epitope vaccines can display dominant epitopes of different genotypes and produce antibodies against multiple genotypes. This vaccine screens the main antigenic epitopes of the virus, simulates the antigenic conformation, connects the antigenic epitope genes in series using a linker, and then expresses and purifies them through a prokaryotic or eukaryotic expression system. Epitope nanoparticles further express multiple antigenic epitopes on regular icosahedral particles formed by skeleton proteins, simulating the natural conformation of the epitopes on the surface of the virus, which is expected to enhance the immunogenicity of the antigenic epitopes. Therefore, it is of great practical significance to develop a safe, efficient and low-cost method for preparing FMDV epitope nanoparticles using a prokaryotic expression system.

[0005] Epitope vaccines have the advantages of good safety, strong specificity and saving immune potential, but they have defects such as small relative molecular mass, weak immunogenicity and easy decomposition, which makes it difficult to cause a strong and lasting immune response in the body. Therefore, how to more fully display the epitope becomes particularly important. The present invention increases the molecular weight of antigenic epitopes by using nanoparticles self-assembled by skeleton proteins, fully displays the antigenic epitopes on the surface of the particles, and simultaneously connects multiple peptide segments with immune enhancement effects in series to enhance the antigen presentation and immune stimulation effects of the nanoparticles in the present invention. Using self-assembled particles as the skeleton, the serially connected viral epitopes and immunopotentiators are independently selected to provide a new strategy for the rapid construction of more effective and broad-spectrum viral vaccines, as well as the development of vaccines for other emerging and sudden infectious diseases. Summary of the invention

[0006] The purpose of the present invention is to provide an AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticle obtained by soluble expression and assembly using a prokaryotic expression system, as well as a preparation method and related uses of the nanoparticle. The AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticle of the present invention can be used to prepare a vaccine to prevent diseases caused by type A and type O foot-and-mouth disease viruses. In addition, the nanoparticle skeleton used in the present invention can also be used to tandem epitopes of other viruses to prepare vaccines for related viruses.

[0007] In order to achieve the above object, the present invention adopts the following technical means:

[0008] The present invention discloses an AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticle, wherein the AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticle is prepared by the following method:

[0009] 1) The GH loop and carboxyl terminal epitopes of the VP1 protein of type A and type O foot-and-mouth disease virus and the T cell epitopes of the 3A protein were selected and connected in series with the backbone protein A. The sequences were optimized and synthesized according to the codon preference of Escherichia coli. The optimized gene sequence is shown in SEQ ID No. 1, and the encoded amino acid sequence is shown in SEQ ID No. 3;

[0010] 2) Select multiple peptides with immune enhancement effects, connect them in series with backbone protein B, optimize and synthesize the sequences according to the codon preference of Escherichia coli, the optimized gene sequence is shown in SEQ ID No. 2, and the encoded amino acid sequence is shown in SEQ ID No. 4;

[0011] 3) The two gene sequences synthesized in steps 1) and 2) are cloned into a dual-expression prokaryotic vector in sequence, and the AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles are obtained after prokaryotic system expression, purification, and self-assembly.

[0012] Among them, preferably, the dual expression prokaryotic vector is the dual expression prokaryotic vector pETDuet-1.

[0013] Wherein, preferably, the purification refers to purification through a nickel column affinity chromatography resin column.

[0014] Among them, preferably, the AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles are spherical with a diameter of 25-30 nm.

[0015] Furthermore, the present invention also proposes the use of the AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles in the preparation of vaccines for preventing diseases caused by type A and type O foot-and-mouth disease viruses.

[0016] In recent years, with the development of nanoscience, platforms such as virus-like particles and nanoparticles have emerged. With the development of computer technology, more and more self-assembled symmetrical nano protein skeletons (nanocages) have been designed by using bioinformatics. The nanocage structure developed using natural proteins has higher stability and is widely used in biomedicine such as vaccines and drug delivery, with broad development prospects. Related research reports that ultra-stable protein nano skeletons can be obtained by computational screening and site modification of natural proteins, and the protein skeleton used in the present invention is obtained from this. It is self-assembled from 60 subunits, in which every three subunits form a trimer subunit, and the overall assembly forms a regular dodecahedral nanocage. And the N-terminus of the protein skeleton extends outward, and gene fusion can be flexibly performed. And the nanocage structure is stable, and gene fusion is efficient; it has a large internal volume, and the entrance and exit channels of the nanocage are controllable; it can carry a variety of functional proteins. The display of antigenic epitopes by self-assembled protein skeletons can enhance the immunogenicity of antigenic epitopes, induce stronger humoral and cellular immune responses, and can be used as an ideal vaccine platform.

[0017] The present invention increases the molecular weight of antigenic epitopes by using nanoparticles self-assembled by skeleton proteins, fully displays antigenic epitopes on the particle surface, and simultaneously connects multiple peptide segments with immune enhancement effects in series to enhance the antigen presentation and immune stimulation effects of the nanoparticles in the present invention. Using self-assembled particles as the skeleton, the serially connected viral epitopes and immune enhancers are independently selected, providing a new strategy for rapidly constructing more effective and broad-spectrum viral vaccines, as well as developing vaccines for other emerging and sudden infectious diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 For restriction enzyme digestion identification of plasmid;

[0019] Wherein, M: DNA Marker, DL10 000; P: Nde I and EcoR V double restriction enzyme digestion of SEQ ID No 2 synthetic plasmid; T: Nco I and BamH I restriction enzyme digestion of SEQ ID No 1 synthetic plasmid;

[0020] Figure 2 PCR identification of SEQ ID No 2 in the constructed expression plasmid;

[0021] Wherein, M: DNA Marker, DL5000; 1-9: bacterial sample; 10: positive control;

[0022] Figure 3 SDS-PAGE (left) and Western Blotting (right) analysis of the recombinant protein;

[0023] Wherein, M: protein molecular weight standard; 1: recombinant protein;

[0024] Figure 4 This is a transmission electron microscope photo of the nanoparticles;

[0025] Figure 5 The results of ELISA test for the level of specific antibodies against type O foot-and-mouth disease;

[0026] Figure 6 It is the ELISA test result of the level of specific antibodies against type A foot-and-mouth disease;

[0027] Figure 7 The results of neutralizing antibody test for type O foot-and-mouth disease;

[0028] Figure 8 This is the result of neutralizing antibody test for type A foot-and-mouth disease. DETAILED DESCRIPTION

[0029] The following examples are used to further describe the present invention, and the advantages and disadvantages of the present invention will become clearer as the description proceeds. However, the following examples are exemplary only and are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0030] Example 1 Preparation of AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles

[0031] 1. Optimization and synthesis of gene codons for foot-and-mouth disease virus epitope nanoparticles

[0032] Based on the published A-type (A / HY / CHA / 2013) and O-type (O / BY / CHA / 2010) foot-and-mouth disease virus sequences (GenBabnk accession numbers: AMR60831 and AET43040), the GH loop and carboxyl terminal epitopes of the VP1 protein and the T cell epitopes of the 3A protein were selected and connected in series with the backbone protein A. According to the codon preference of Escherichia coli, the sequence was optimized and synthesized, and Nco I and BamH I restriction sites were introduced at both ends. The optimized gene sequence is shown in SEQ ID No.1, and the encoded amino acid sequence is shown in SEQ ID No.3; multiple peptides with immune enhancement effects were selected and connected in series with the backbone protein B. According to the codon preference of Escherichia coli, the sequence was optimized and synthesized, and Nde I and EcoR V restriction sites were introduced at both ends. The optimized gene sequence is shown in SEQ ID No.2, and the encoded amino acid sequence is shown in SEQ ID No.4.

[0033] 2. Construction of recombinant expression vector of foot-and-mouth disease virus epitope nanoparticles

[0034] (1) Enzyme digestion of fragments and vectors

[0035] According to the instructions of the endonuclease, the synthesized plasmid containing the target gene (SEQ ID No.1 or SEQ ID No.2) was digested by enzymes. The reaction system was as follows: 1 μg (1 μL) of plasmid was added to 50 μL of enzyme digestion reaction system, which contained 5 μL of endonuclease buffer and 2 μL of endonucleases Nco I and BamH I or Nde I and EcoRV, and added to 50 μL with deionized water. Digestion was performed at 37°C for 4 hours, and then agarose gel electrophoresis was used to confirm that the digestion product had been cut ( Figure 1 ), followed by gel recovery. The dual expression vector pETDuet-1 was digested with Nde I and EcoRV as above, and gel recovered.

[0036] (2) Gel recovery of enzyme digestion products

[0037] Use a gel imaging system to observe the electrophoresis results of the enzyme digestion products and cut out the target fragments, and use a common agarose gel DNA recovery kit to recover and purify the target fragments. The specific steps are as follows:

[0038] Cut the target DNA band from the agarose gel under UV light, put it into a clean centrifuge tube and weigh it. 100 mg of gel is regarded as 100 μL volume. Add 3 times volume of GSB solution, melt the gel in a 55℃ water bath for 6-10 minutes, mix intermittently to ensure that the gel block is completely melted. When the gel is completely melted, observe the color of the solution. If the color is purple, add 3M sodium acetate (pH5.2) to adjust the color to the same as GSB. After the melted gel solution cools to room temperature, add the adsorption column and let it stand for 1 minute. Centrifuge at 10000×g for 1 minute, and discard the liquid in the collection tube.

[0039] Add 650 μL of WB solution, centrifuge at 10,000×g for 1 min, discard the liquid in the collection tube, centrifuge at 10,000×g for 1-2 min, and remove the collection tube.

[0040] Place the adsorption column in a clean centrifuge tube, open the cover and let it stand for 1 minute to allow the residual ethanol to evaporate. Add 30-50 μL of deionized water to the center of the column and let it stand at room temperature for 1 minute. Then centrifuge at 10,000×g for 1 minute to elute the DNA and store at -20°C.

[0041] (3) Ligation reaction

[0042] The two products were connected according to the molar ratio of the vector and the recovered fragment. The reaction system was: 2 μL of the target fragment (SEQ ID No. 2), 1 μL of the vector pETDuet-1 digested with Nde I and EcoRV, 1 μL of T4 DNA ligase (1U / μL), 1 μL of 10×T4 DNA ligation buffer, and ultrapure water was added to a total volume of 10 μL. After mixing, the ligation was carried out at 4°C overnight or at 16°C for 4 hours.

[0043] (4) Transformation of TOP10 clones

[0044] Take 5 μL of the ligation product and add it to 100 μL of TOP10 competent cells. After gentle mixing, place it on ice for 30 min, heat shock it at 42°C for 90 sec, immediately place it on ice for 5 min, add 800 μL of LB liquid culture medium preheated at 37°C, shake and culture it at 37°C for 1 h, spread the culture evenly on an LB agar plate containing 50 μg / mL ampicillin, and culture it at 37°C for about 16 h.

[0045] (5) Identification of recombinant plasmid

[0046] Use a sterile toothpick to pick up uniform-sized colonies on the LB plate and inoculate them into LB liquid culture medium. Cultivate with shaking at 37°C for 16 hours. Inoculate the bacterial liquid after overnight culture of different numbers into 10 μL PCR buffer system, identify by bacterial liquid PCR method, and observe the results by agarose gel electrophoresis ( Figure 2 ).

[0047] As described above (1)-(5), the gene fragment of SEQ ID No. 1 was inserted between the Nco I and BamH I restriction sites of the recombinant plasmid obtained in (5), and the resulting positive plasmid was named pTP.

[0048] 3. Expression, purification and immunoblotting analysis of AO bivalent FMDV epitope chimeric nanoparticles

[0049] (1) Expression of recombinant proteins

[0050] Transform pTP into E. coli BL21 (DE3) strain. Use ampicillin to screen positive clones. Select positive clones in LB medium and culture overnight at 37°C and 220rpm. Inoculate the above bacterial solution into 1L LB medium at 1:100, shake at 37°C and 220rpm until the OD600 value of the bacterial solution is about 0.8, add isopropylthiogalactoside (IPTG) to a final concentration of 0.5mM, induce expression overnight at 20°C, and then collect the bacterial precipitate by centrifugation at 5000rpm and 30min.

[0051] (2) Purification of expressed recombinant protein

[0052] Resuspend the bacterial precipitate with 10-20 ml of Buffer A (500 mM NaCl, 20 mM Tris-HCl, 20 mM Imidazole, 1 mM DTT, pH = 8.0) treated in an ice bath, and disrupt the bacterial cells by ultrasound on ice. Centrifuge the ultrasonic lysed bacterial solution at 12000 r / min for 30 min at 4°C, and keep the supernatant. Transfer the supernatant to a chromatography column pre-loaded with nickel affinity chromatography resin equilibrated with Buffer A, mix the supernatant with Ni-NTAResins, bind at room temperature for about 1 hour, wash away non-specifically bound impurities with 10 times the volume of the resin Buffer A and 5% Buffer B (500 mM NaCl, 20 mM Tris-HCl, 500 mM Imidazole, 1 mM DTT, pH = 8.0), and elute the target protein with Buffer B, 1 ml each time, and repeat elution 6-7 times. The above samples were subjected to SDS-PAGE electrophoresis and Western Blotting of His tag, and the results showed that the expected size of protein was obtained ( Figure 3 ).

[0053] 4. Assembly of AO bivalent FMDV-FMDV epitope chimeric nanoparticles

[0054] The AO bivalent foot-and-mouth disease virus epitope nanoparticles of the present invention are self-assembled particles, and the self-assembled nanoparticles can be obtained after purification by nickel column affinity chromatography resin chromatography column. The assembly effect is observed by conventional transmission electron microscopy. The specific method is to add 10 μL of sample to a 300-mesh copper mesh, adsorb at room temperature for 2-3 minutes, dry the copper mesh with filter paper, stain with 3% phosphotungstic acid, and observe with a Hitachi H-7100FA transmission electron microscope. The results show that the obtained nanoparticles are spherical with a diameter of 25-30 nm ( Figure 4 ).

[0055] Example 2 Detection of the immune efficacy of foot-and-mouth disease virus epitope nanoparticles in guinea pigs

[0056] Fifteen guinea pigs weighing about 200g were divided into three groups. The first group was immunized with AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles, and the second and third groups were immunized with nanoparticles without immune enhancement protein and epitope protein as controls. Blood was collected weekly after immunization to separate serum, and blood was collected continuously for four weeks to detect specific antibodies and neutralizing antibodies.

[0057] (1) Guinea pig serum specific antibody detection test

[0058] Add foot-and-mouth disease virus antigen to the ELISA plate coated with foot-and-mouth disease rabbit antibody and let it stand at 37°C for 1 hour. After that, dilute the guinea pig serum and positive and negative control serum with PBST in multiple ratios on the micro-hemagglutination plate, transfer the serum to the ELISA plate, and incubate at 37°C for 1 hour. Wash 3 times with PBST, add rabbit anti-guinea pig IgG-HRP working solution (50μL), seal the plate, and incubate at 37°C for 30 minutes. After washing 3 times with PBST, 50μL of substrate solution was added to each well and incubated at 37°C for 15 minutes. Then add 50μL of stop solution to each well to terminate the color reaction, and detect the optical density (OD value) at 450nm. The levels of guinea pig serum type A and type O foot-and-mouth disease specific antibodies were tested, and the results showed that the serum antibody level of the chimeric nanoparticle immunization group was significantly higher than that of the control ( Figure 5 , Figure 6 ), indicating that the chimeric nanoparticles have good immunogenicity and can stimulate the animal body to produce type A and type O foot-and-mouth disease-specific antibodies.

[0059] (2) Guinea pig serum neutralizing antibody detection test

[0060] Guinea pig serum diluted with physiological saline was inactivated at 56°C for 30 min, and then serially diluted 2-fold with DMEM medium on a 96-well cell culture plate. Four wells were prepared for each dilution, and 50 μL of virus solution (100 TCID50) was added to each well. After neutralization at 37°C for 1 h, 100 μL of cell suspension (1×10 5 / mL), placed in a 5% CO2 incubator at 37°C, and observed from 48h to 72h for final judgment. Positive and negative serum controls, virus regression tests, serum toxicity controls, and normal cell controls were set up. According to the Spearman-Karber method, the serum dilution that can protect 50% of the cell wells from cytopathic effects was calculated, which is the neutralizing antibody titer of the test sample. The results of the test on the neutralizing antibody level of guinea pig serum type A and type O foot-and-mouth disease showed that the chimeric nanoparticle immunization group was significantly higher than the control group ( Figure 7 , Figure 8 ), indicating that the nanoparticle vaccine has good immunogenicity.

[0061] The above experiments show that the recombinant protein expressed by the prokaryotic expression system can self-assemble into nanoparticles, and the assembled AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles have good immunogenicity and can be used in the preparation of vaccines to prevent diseases caused by type A and type O foot-and-mouth disease viruses.

[0062] The above is a preferred embodiment of the present invention. It should be pointed out that for those skilled in the art, some modifications or improvements can be made to the nanoparticle skeleton of the present invention, such as changing the viral epitope, etc. Without departing from the spirit of the present invention, these modifications or improvements should also be regarded as the scope of protection required by the present invention. Sequence Listing <110> Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences <120> AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles and preparation method and use thereof <141> 2022-05-09 <160> 4 <170> SIPOSequenceListing 1.0 <210> 1 <211> 1109 <212> DNA <213> artificial sequence <400> 1 ccatgggctc aggaacaagt aaatatagcg ctccccaaaa ccgtcgcggt gacctgggcc 60 cactggccgc gcgcctggca gctcagctgg gtagtggttc tggctcacca ctgctggcag 120 tagaggttag cagccaggat cgtcataaac agaaaatcat cgcgccggca aaacaactgg 180 gttcgggctc tggtagcgct gcgatcgagt tttttgaagg tatggtgcac gacagcatta 240 aaggctccgg ttccggctcg cttccgaacg tgcgcggtga tctgcaagtc ttggcgcaaa 300 aagccgcccg tccgctgccg ggctccggct ctggctctcg tcacaaacag aagatcgtgg 360 cccctgttaa acaaagcttg ggcgggtccg gtggctctgg cggttccggc ggcagcgaaa 420 aggctgccaa agctgaagaa gccgcgcgta aaatggaaga gctcttcaaa aagcacaaga 480 tcgttgcggt cctgcgtgcg aacagcgttg aggaggcaat cgagaaggct gtggcagtct 540 ttgcaggcgg cgttcacttg attgagatca ccttcaccgt tccggatgcg gataccgtta 600 ttaaggcgct gagcgtgtta aaagaaaagg gtgcgattat tggtgcgggt accgtgacca 660 gcgttgagca gtgcagaaaa gcggttgaga gcggcgcgga gttcatcgtg agcccgcatt 720 tagcgagga aattagccaa ttttgtaagg agaagggtgt gttctacatg ccgggtgtaa tgaccccgac ggaattggtt aaagctatga aactgggtca tgacatcctg aaattgttcc cgggtgaagt cgtgggtccg cagttcgtga aggcaatgaa gggtccgttt ccgaatcata gcccggtcaa gtttgtgccg actggtggtg ttaatctgga caacgtttgc aaatggttca aagcggggggt gctggccgtg ggtgttggca aggcgttggt taagggcaag ccggacgagg 1020 1080. tgcgcgaaaa ggctaagaaa ttcgtgaaga agattcgtgg gtgcacgga ggttcgctgg aacaccatca ccaccaccat tagccc <210> 2 <211> 776 <212> DNA <213> artificial sequence <400> 2 catatgcaaa aaataggact agaaataatt aaaaaggcgc ttaagatccc ggcaatgacc 60 attgcaaaaa atgctggtgt ggagggttcc ttgattgtcg agaaaattct gcagagcagc 120 ccggaaggtt cgggctccgg ttctgctaag tttgtggccg catggaccct caaggccgcg 180 gcggggtcgg gcagtggttc tactgcgaaa agcaagaaat tcccgagcta cacggctacc 240 tatcaatttg gttcgggctc tggcagcatg aaccaacata gccataaaga ccacgaaacc 300 gttagaatcg ccgtggtgcg cgcgcgttgg cacgctgaga tcgtggacgc atgtgttagc 360 gccttcgaag ctgctatgcg tgatattggc ggtgatcgtt ttgcagtcga cgttttcgat 420 gtgccgggtg cgtatgagat cccgctgcac gcgcgtaccc tggccgagac gggtcgttac 480 ggcgcggttc tgggtacggc attcgtggtt aatggtggta tttaccgcca tgaatttgta 540 gcgagcgcgg tcatcaacgg catgatgaat gttcagctga acaccggcgt tccagttctg 600 agcgcggtgt tgaccccgca taactatgac aagagcaagg cgcacacctt gctgttctta 660 gcgctgttcg ctgttaaagg catggaagcg gcacgcgcct gcgtggagat cctggcagcg 720 cgtgaaaaga tcgcggcggg ttccttggag catcatcacc accaccataa gatatc 776 <210> 3 <211> 366 <212> PRT <213> artificial sequence <400> 3 Met Gly Ser Gly Thr Ser Lys Tyr Ser Ala Pro Gln Asn Arg Arg Gly 1 5 10 15 Asp Leu Gly Pro Leu Ala Ala Arg Leu Ala Ala Gln Leu Gly Ser Gly 20 25 30 Ser Gly Ser Pro Leu Leu Ala Val Glu Val Ser Ser Gln Asp Arg His 35 40 45 Lys Gln Lys Ile Ile Ala Pro Ala Lys Gln Leu Gly Ser Gly Ser Gly 50 55 60 Ser Ala Ala Ile Glu Phe Phe Glu Gly Met Val His Asp Ser Ile Lys 65 70 75 80 Gly Ser Gly Ser Gly Ser Leu Pro Asn Val Arg Gly Asp Leu Gln Val 85 90 95 Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro Gly Ser Gly Ser Gly Ser 100 105 110 Arg His Lys Gln Lys Ile Val Ala Pro Val Lys Gln Ser Leu Gly Gly 115 120 125 Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Glu Lys Ala Ala Lys Ala 130 135 140 Glu Glu Ala Ala Arg Lys Met Glu Glu Leu Phe Lys Lys His Lys Ile 145 150 155 160 Val Ala Val Leu Arg Ala Asn Ser Val Glu Glu Ala Ile Glu Lys Ala 165 170 175 Val Ala Val Phe Ala Gly Gly Val His Leu Ile Glu Ile Thr Phe Thr 180 185 190 Val Pro Asp Ala Asp Thr Val Ile Lys Ala Leu Ser Val Leu Lys Glu 195 200 205 Lys Gly Ala Ile Ile Gly Ala Gly Thr Val Thr Ser Val Glu Gln Cys 210 215 220 Arg Lys Ala Val Glu Ser Gly Ala Glu Phe Ile Val Ser Pro His Leu 225 230 235 240 Asp Glu Glu Ile Ser Gln Phe Cys Lys Glu Lys Gly Val Phe Tyr Met 245 250 255 Pro Gly Val Met Thr Pro Thr Glu Leu Val Lys Ala Met Lys Leu Gly 260 265 270 His Asp Ile Leu Lys Leu Phe Pro Gly Glu Val Val Gly Pro Gln Phe 275 280 285 Val Lys Ala Met Lys Gly Pro Phe Pro Asn His Ser Pro Val Lys Phe 290 295 300 Val Pro Thr Gly Gly Val Asn Leu Asp Asn Val Cys Lys Trp Phe Lys 305 310 315 320 Ala Gly Val Leu Ala Val Gly Val Gly Lys Ala Leu Val Lys Gly Lys 325 330 335 Pro Asp Glu Val Arg Glu Lys Ala Lys Lys Phe Val Lys Lys Ile Arg 340 345 350 Gly Cys Thr Glu Gly Ser Leu Glu His His His His His His 355 360 365 <210> 4 <211> 255 <212> PRT <213> artificial sequence <400> 4 Met Gln Lys Ile Gly Leu Glu Ile Ile Lys Lys Ala Leu Lys Ile Pro 1 5 10 15 Ala Met Thr Ile Ala Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val 20 25 30 Glu Lys Ile Leu Gln Ser Ser Pro Glu Gly Ser Gly Ser Gly Ser Ala 35 40 45 Lys Phe Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Gly Ser Gly Ser 50 55 60 Gly Ser Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr 65 70 75 80 Gln Phe Gly Ser Gly Ser Gly Ser Met Asn Gln His Ser His Lys Asp 85 90 95 His Glu Thr Val Arg Ile Ala Val Val Arg Ala Arg Trp His Ala Glu 100 105 110 Ile Val Asp Ala Cys Val Ser Ala Phe Glu Ala Ala Met Arg Asp Ile 115 120 125 Gly Gly Asp Arg Phe Ala Val Asp Val Phe Asp Val Pro Gly Ala Tyr 130 135 140 Glu Ile Pro Leu His Ala Arg Thr Leu Ala Glu Thr Gly Arg Tyr Gly 145 150 155 160 Ala Val Leu Gly Thr Ala Phe Val Val Asn Gly Gly Ile Tyr Arg His 165 170 175 Glu Phe Val Ala Ser Ala Val Ile Asn Gly Met Met Asn Val Gln Leu 180 185 190 Asn Thr Gly Val Pro Val Leu Ser Ala Val Leu Thr Pro His Asn Tyr 195 200 205 Asp Lys Ser Lys Ala His Thr Leu Leu Phe Leu Ala Leu Phe Ala Val 210 215 220 Lys Gly Met Glu Ala Ala Arg Ala Cys Val Glu Ile Leu Ala Ala Arg 225 230 235 240 Glu Lys Ile Ala Ala Gly Ser Leu Glu His His His His His His 245 250 255

Claims

1. An AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticle, characterized in that: The AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles are prepared by the following method: 1) The GH loop and carboxyl terminal epitopes of the VP1 protein of type A and type O foot-and-mouth disease virus and the T cell epitopes of the 3A protein were selected and connected in series with the backbone protein A. The sequences were optimized and synthesized according to the codon preference of Escherichia coli. The optimized gene sequence is shown in SEQ ID No. 1, and the encoded amino acid sequence is shown in SEQ ID No. 3; 2) Select multiple peptides with immune enhancement effects, connect them in series with backbone protein B, optimize and synthesize the sequences according to the codon preference of Escherichia coli, the optimized gene sequence is shown in SEQ ID No. 2, and the encoded amino acid sequence is shown in SEQ ID No. 4; 3) The two gene sequences synthesized in steps 1) and 2) are cloned into a dual-expression prokaryotic vector in sequence, and the AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles are obtained after prokaryotic system expression, purification, and self-assembly.

2. The AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles according to claim 1, characterized in that: The dual expression prokaryotic vector is the dual expression prokaryotic vector pETDuet-1.

3. The AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles according to claim 1, characterized in that: The purification refers to purification through nickel column affinity chromatography resin chromatography column.

4. The AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles according to claim 1, characterized in that: The AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles are spherical and have a diameter of 25-30 nm.

5. Use of the AO bivalent foot-and-mouth disease virus epitope chimeric nanoparticles according to any one of claims 1 to 4 in the preparation of type A and type O foot-and-mouth disease virus vaccines.

Citation Information

Patent Citations

  • Pig foot-and-mouth disease virus O type and A type Fc polypeptide bivalent vaccine, as well as preparation method and application thereof

    CN108273054A

  • Fusion protein, viroid particles and vaccine of porcine foot-and-mouth disease virus and porcine rotavirus and preparation method

    CN111253494A

  • Foot-and-mouth disease virus bivalent multi-epitope recombinant virus-like particle and application thereof

    CN111548395A

  • EB virus gHgLgp42 protein containing self-assembled nanoparticles, and preparation method and applications thereof

    CN113144187A

  • Tandem expression type VLP subunit vaccine for foot and mouth disease virus

    CN113908266A